| abstract |
The invention relates to a polypeptide comprising a crystallizable fragment (Fc) region of IgG for use in prevention or treatment of a disease, in particular of a disease affecting the central nervous system. The polypeptide is administered locally to compartments, in particular to the central nervous system. The Fc region comprises the mutations I253N and H435Q and an H at position 310 resulting in reduced affinity to the neonatal Fc receptor (FcRn), resulting in an increased brain to serum concentration of the polypeptide. |